- Home
- FBIOP vs BMRN Comparison
FBIOP vs BMRN Comparison
Compare FBIOP & BMRN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FBIOP
- BMRN
- Stock Information
- Founded
- FBIOP N/A
- BMRN 1996
- Country
- FBIOP United States
- BMRN United States
- Employees
- FBIOP 186
- BMRN N/A
- Industry
- FBIOP Biotechnology: Pharmaceutical Preparations
- BMRN Biotechnology: Pharmaceutical Preparations
- Sector
- FBIOP Health Care
- BMRN Health Care
- Exchange
- FBIOP Nasdaq
- BMRN Nasdaq
- Market Cap
- FBIOP N/A
- BMRN N/A
- IPO Year
- FBIOP N/A
- BMRN 1999
- Fundamental
- Price
- FBIOP $5.08
- BMRN $66.09
- Analyst Decision
- FBIOP
- BMRN Buy
- Analyst Count
- FBIOP 0
- BMRN 20
- Target Price
- FBIOP N/A
- BMRN $94.16
- AVG Volume (30 Days)
- FBIOP N/A
- BMRN 1.5M
- Earning Date
- FBIOP N/A
- BMRN 10-29-2024
- Dividend Yield
- FBIOP N/A
- BMRN N/A
- EPS Growth
- FBIOP N/A
- BMRN 118.12
- EPS
- FBIOP N/A
- BMRN 1.68
- Revenue
- FBIOP N/A
- BMRN $2,752,809,000.00
- Revenue This Year
- FBIOP N/A
- BMRN $18.72
- Revenue Next Year
- FBIOP N/A
- BMRN $9.64
- P/E Ratio
- FBIOP N/A
- BMRN $39.04
- Revenue Growth
- FBIOP N/A
- BMRN 19.14
- 52 Week Low
- FBIOP N/A
- BMRN $65.35
- 52 Week High
- FBIOP N/A
- BMRN $99.56
- Technical
- Relative Strength Index (RSI)
- FBIOP 49.96
- BMRN 36.46
- Support Level
- FBIOP $5.01
- BMRN $65.80
- Resistance Level
- FBIOP $5.86
- BMRN $67.00
- Average True Range (ATR)
- FBIOP 0.51
- BMRN 1.35
- MACD
- FBIOP -0.03
- BMRN 0.18
- Stochastic Oscillator
- FBIOP 28.99
- BMRN 20.90
About FBIOP Fortress Biotech Inc.
Fortress Biotech Inc is a biopharmaceutical company. The firm is involved in the business of acquiring, developing, and commercializing pharmaceutical and biotechnology products. Its product portfolio encompasses Qbrexza, Accutane, Amzeeq, Zilxi, Targadox, Ximino, and Exelderm. The business activities of the group are functioned through Dermatology Product Sales, and Pharmaceutical and Biotechnology Product Development. It derives the majority of its revenues from Dermatology segment. Its subsidiaries also operate in biotechnology, pharmaceutical, oncology, therapeutics sectors.